Nicox announces attendance at upcoming conferences
July 19 2024 - 12:30AM
Press Release |
Nicox announces attendance at upcoming conferences |
July 19th, 2024 – release
at 7:30 am CETSophia Antipolis, FranceNicox
SA (Euronext Growth Paris: FR0013018124, ALCOX), an
international ophthalmology company, today announced its attendance
at several upcoming international conferences:
- H.C. Wainwright 4th Annual
Ophthalmology Virtual Conference, August 15, 2024
(Virtual)
- H.C. Wainwright 26th Annual
Global Investment Conference, September 9-11, 2024 (New
York)
- Investor Access, October
15-16, 2024 (Paris)
- AAO (American Academy of
Ophthalmology) 2024, October 18-21, 2024 (Chicago)
|
About Nicox |
Nicox SA is an international ophthalmology company developing
innovative solutions to help maintain vision and improve ocular
health. Nicox’s lead program in clinical development is NCX 470
(bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye
drop, for lowering intraocular pressure in patients with open-angle
glaucoma or ocular hypertension. Nicox generates revenue from
VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch +
Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in
multiple geographies, including to Harrow, Inc. in the U.S., and
Ocumension Therapeutics in the Chinese and in the majority of
Southeast Asian markets. Nicox, headquartered in Sophia Antipolis,
France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX)
and is part of the CAC Healthcare index. For more information
www.nicox.com |
Analyst coverage |
H.C. Wainwright & Co Yi Chen New York, U.S. |
|
The views expressed by analysts in their coverage of Nicox are
those of the author and do not reflect the views of Nicox.
Additionally, the information contained in their reports may not be
correct or current. Nicox disavows any obligation to correct or to
update the information contained in analyst reports. |
Contacts |
|
NicoxGavin SpencerChief Executive OfficerT +33
(0)4 97 24 53 00communications@nicox.com |
Media / Investors Sophie Baumont Cohesion Bureau
+33 6 27 74 74 49 sophie.baumont@cohesionbureau.com |
Disclaimer |
The information contained in this document may be modified without
prior notice. This information includes forward-looking statements.
Such forward-looking statements are not guarantees of future
performance. These statements are based on current expectations or
beliefs of the management of Nicox S.A. and are subject to a number
of factors and uncertainties that could cause actual results to
differ materially from those described in the forward-looking
statements. Nicox S.A. and its affiliates, directors, officers,
employees, advisers or agents, do not undertake, nor do they have
any obligation, to provide updates or to revise any forward-looking
statements.Risks factors which are likely to have a material effect
on Nicox’s business are presented in section 3 of the “Rapport
Annuel 2023” which is available on Nicox’s website
(www.nicox.com).Finally, this press release may be drafted in the
French and English languages. If both versions are interpreted
differently, the French language version shall prevail. |
Nicox S.A.Sundesk Sophia Antipolis, Bâtiment C,
Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4
97 24 53 00 |
- EN_Nicox Conferences 2024_FINAL